Biogen (BIIB) Misses Q1 EPS by 6c; Revs Light
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Biogen Reports First Quarter 2015 Revenues of $2.6 Billion
April 24, 2015 7:00 AM EDTMultiple sclerosis portfolio gains share globally with ongoing TECFIDERA® rollout in Europe and launch of PLEGRIDY®
Company advances research pipeline and development efforts in Alzheimers disease, secondary progressive MS and neurological repair for MS
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen Inc. (NASDAQ: BIIB) today reported first quarter 2015 results, including revenues of $2.6 billion, a 20% increase compared to the first quarter of 2014. Non-GAAP diluted earnings per share (EPS) for the first quarter of 2015 were $3.82, an increase of 55% over the first quarter of 2014.... More
